Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Research & Development (2018 - 2025)

Inmune Bio (INMB) has disclosed Research & Development for 8 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 68.33% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.7 million through Dec 2025, down 37.71% year-over-year, with the annual reading at $20.7 million for FY2025, 37.71% down from the prior year.
  • Research & Development hit $2.3 million in Q4 2025 for Inmune Bio, down from $4.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.1 million in Q3 2024 to a low of $2.3 million in Q4 2025.
  • Historically, Research & Development has averaged $5.6 million across 5 years, with a median of $5.5 million in 2022.
  • Biggest five-year swings in Research & Development: skyrocketed 394.35% in 2021 and later crashed 68.33% in 2025.
  • Year by year, Research & Development stood at $7.1 million in 2021, then plummeted by 51.75% to $3.4 million in 2022, then surged by 76.16% to $6.0 million in 2023, then grew by 22.41% to $7.4 million in 2024, then plummeted by 68.33% to $2.3 million in 2025.
  • Business Quant data shows Research & Development for INMB at $2.3 million in Q4 2025, $4.9 million in Q3 2025, and $5.8 million in Q2 2025.